Cart

Cart


Research & Trial Information

SCHEMA AFT-25 COMET

Protocol #: AFT-25 COMET

Cancer Type: Breast DCIS

Inclusion Criteria:

  1. New diagnosis of DCIS without invasive cancer; date of diagnosis defined as the date of the first pathology report that diagnosed the patient with DCIS

2. Unilateral, bilateral, unifocal, or multifocal DCIS.

3. ADH/borderline DCIS.

4. A patient who has had a lumpectomy with positive margins as part of their treatment for a current DCIS diagnosis is eligible (post-excision mammogram required at enrollment to establish a new baseline).

5. No previous history of breast cancer (DCIS or invasive cancer) in either breast prior to current DCIS diagnosis.

6. 40 years of age or older at time of DCIS diagnosis.

7. ECOG performance status 0 or 1.

8. No contraindication for surgery.

9.Baseline imaging:

o unilateral DCIS: contralateral normal mammogram ≤ 6 months of registration and ipsilateral breast imaging ≤ 90 days of registration (must include ipsilateral mammogram; can also include ultrasound or breast MRI)

o bilateral DCIS: bilateral breast imaging ≤ 90 days of registration (must include bilateral mammogram; can also include ultrasound or breast MRI)

10. Pathologic criteria: o Any grade I DCIS

o Any grade II DCIS without comedonecrosis

o Absence of invasion or microinvasion

o Diagnosis confirmed on core needle, vacuum-assisted or surgery ≤ 90 days of registration

o ER(+) and/or PR(+) by IHC (≥ 10% staining or Allred score ≥ 4)

o HER2 0, 1+, or 2+ by IHC if HER2 testing is performed

11. Histology slides reviewed and agreement between two clinical pathologists (not required to be at same institution) that pathology fulfils COMET eligibility criteria. In cases of disagreement between the two pathology reviews about whether or not a case fulfils the eligibility criteria, a third pathology review will be required.

12. At least two sites of biopsy for those cases where mammographic extent of calcifications exceeds 4 cm, with second biopsy benign or both sites fulfilling pathology eligibility criteria.

13. Amenable to follow up examinations.

Exclusion Criteria:

1. Male DCIS.

2. Grade II DCIS with comedonecrosis.

3. Papillary or micropapillary DCIS.

4. Concurrent diagnosis of invasive or microinvasive breast cancer in either breast.

5. Documented mass on examination or imaging at site of DCIS prior to biopsy yielding diagnosis of DCIS, with exception of fibroadenoma at a distinct/separate site from site of DCIS. In cases of uncertainty about whether the mass was present on physical examination prior to biopsy, the following criteria should be applied: if mammogram noting abnormal findings is diagnostic MMG = symptomatic/if mammogram noting abnormal findings is screening MMG = asymptomatic.

6. Bloody nipple discharge.

7. Mammographic finding of BIRADS 4 or greater within 6 months of registration at site other than that of known DCIS, without pathologic assessment.

8. Use of investigational cancer agents within 6 weeks prior to diagnosis.

9. Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process.

 

 

 

 



Research & Trial Information

SCHEMA A011401

Protocol#: Alliance – A011401 BWELL

Cancer Type: Cancer Control/Prevention

Eligibility.

Documentation of Disease:

    • Subjects must have histologically confirmed invasive breast cancer and registration must occur within 12 months after the first histologic diagnosis of invasive breast cancer.
    • A core biopsy interpreted as invasive cancer meets this criterion; if no core biopsy is performed, the date of first histologic diagnosis will be the date of first surgical procedure that identifies invasive cancer (biopsy, lumpectomy or mastectomy). Neoadjuvant subjects should have no evidence of clinical T4 disease prior to chemotherapy and surgery. See eligible cTNM classifications below. Eligibility for neoadjuvant patients can be defined by either clinical stage prior to therapy or pathologic stage at surgery. If patient is eligible based on either, they are eligible for the study.
    • Bilateral breast carcinoma is allowed provided diagnoses are synchronous – that is, within 3 months of one another – and at least one of the two breast carcinomas meet the eligibility criteria and neither is Her-2 positive or inflammatory.
    • No evidence of metastatic disease.
    • Her-2 negative, defined as:
    • ISH ratio of < 2.0 (if performed).
    • IHC staining of 0-2+ (if performed).
    • Deemed to not be a candidate for Her-2 directed therapy.

    Eligible TNM Stages include:

    • ER and PR negative (defined as <1% staining for ER and PR by IHC): T2 or T3 N0, T0-3N1-3.

    Note: Patients with T1, N1mi disease are NOT eligible.

    • ER and/or PR positive (defined as ≥ 1% staining for ER and/or PR on IHC): T0-3N1- 3 or T3N0.

    Note: Patients with T1-2, N1mi disease are NOT eligible.

    The eligibility of neo-adjuvant subjects can be assessed on the basis of

    cTNM or ypTNM. The same eligible TNM combinations apply; patients

    may be eligible if they meet eligibility requirements at either time point,

    as long as they do not have T4 disease prior to therapy.

    • No history of invasive breast cancer in 5 years prior to study registration other than the current diagnosis (prior DCIS at any time is acceptable).
    • Patients must have had a bilateral mammogram within 12 months prior to registration, unless the initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required. (Subjects with bilateral total mastectomies do not require imaging).
    • Investigations, including chest X-ray or CT chest, bone scan (with radiographs of suspicious areas) and abdominal ultrasound or liver scan or CT abdomen have been performed between the first histologic diagnosis and the time of registration as detailed below.
    • Chest X-Ray, 2 views (or Chest CT, or PET/CT) is required only if clinically indicated or recommended by NCCN guidelines.
    • Bone scans (with x-rays of abnormal areas) are required only if clinically indicated or recommended by NCCN guidelines.
    • Abdominal imaging is required only if clinically indicated or recommended by NCCN guidelines.
    1. Prior Treatmentdays prior to registration.
    2. All adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21
    • All triple negative patients must receive chemotherapy of the treating physician’s choice.
    • ER/PR+ patients must receive chemotherapy (of the treating physician’s choice) unless Oncotype Dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine therapy alone.
    • Patients may have breast reconstruction during protocol participation, but definitive breast cancer surgery must be completed at least 21 days prior to registration.

    Concomitant biologic therapy, hormonal therapy, and bisphosphonates are acceptable.

    • Surgical margins must be clear of invasive carcinoma. If there is microscopic residual ductal in situ disease present at lumpectomy or total mastectomy margins, further excision is highly recommended. If further excision is not undertaken, the subject may still be entered on study, provided that in addition to breast or chest wall irradiation, a boost to the tumor bed is delivered. In situ lobular disease at the margin is acceptable.
    • All subjects (both adjuvant and neoadjuvant) must have sentinel lymph node biopsy and/or axillary lymph node dissection.

    Sentinel lymph node biopsy alone is allowed in the following instances:

    1. Sentinel lymph node biopsy is negative: pN0.
    2. Sentinel lymph node biopsy is positive for isolated tumor cells only: pN0 (i+).
    3. Clinically node negative, T1-2 tumors with sentinel lymph node biopsy positive in ≤ 2 lymph nodes without matted nodes and undergoing breast conserving surgery and tangential whole breast irradiation, or undergoing mastectomy and chest wall irradiation.
    4. For patients who had a positive node prior to neoadjuvant chemotherapy, sentinel node alone is allowed after neoadjuvant therapy if:
    1. Sentinel node biopsy is negative after chemotherapy and either at least 2 sentinel nodes were removed or a clip was placed in the involved node prior to treatment.
    2. ≤ 2 lymph nodes are positive for cancer and the patient is participating in A011202.
    • All women who undergo breast conserving therapy must receive concomitant radiotherapy. Radiation after mastectomy is to be administered according to prespecified institutional guidelines. Radiation must be completed at least 21 days prior to registration.
    • Patients with hormone receptor positive breast cancer as defined above must plan to receive at least 5 years of adjuvant hormonal therapy in the form of tamoxifen or an aromatase inhibitor, alone or in combination with ovarian suppression. (NOTE: for patients with ER and PR staining in less than 5% of cells, hormonal therapy for at least 5 years is strongly recommended but not required). hormonal therapy can be initiated prior to or during protocol therapy.
  1. Participants must be women.
  2. Age ≥ 18 years.
  3. ECOG Performance Status 0 or 1.
    1. Comorbid Conditions.
    • No history of other malignancy within the past 4 years, except for malignancies with a >95% likelihood of cure (e.g. non-melanoma skin cancer, papillary thyroid cancer, in situ cervical cancer). Patients cannot have metastatic breast or other cancer.
    • No diabetes mellitus currently treated with insulin or sulfonylureas.
    • No history of serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet.
    • No history of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility.
    • No prior bariatric surgery or planning to undergo this procedure within the next 2 years after study registration.
    • No comorbid conditions that would cause life expectancy of less than 5 years.
    • No history of psychiatric disorders that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder) or prevent the patient from giving informed consent.
    1. Other
    • BMI ≥27 kg/m2 documented within 56 days prior to study registration. The most recent BMI obtained must be used for eligibility. If most recent BMI is <27 then the patient is not eligible to enroll.
    • Self-reported ability to walk at least 2 blocks (at any pace).

    Not participating in another weight loss, physical activity or dietary intervention clinical trial. Co-enrollment in some trials involving pharmacologic therapy is allowed. Participants in both arms are also allowed to pursue weight loss and physical activity programs on their own, as long as these programs are not provided as part of a clinical trial.

 

 

 

 

 


Genesys Hurley Cancer Institute

302 Kensington Avenue
Flint, MI 48503

810-762-8226 | 888-762-8675

Genesys Health System
Hurley Medical Center
Michigan Cancer Consortium

Newsletter

Ⓒ 2018 Genesys Hurley Cancer Institute | All Rights Reserved.

Cart

Cart